Core Viewpoint - Beta Bionics, Inc. has faced significant stock declines following disappointing preliminary fourth-quarter 2025 performance metrics, raising concerns among investors regarding the company's growth prospects [4][5]. Group 1: Company Performance - On January 9, 2026, Beta Bionics reported lower-than-expected new patient starts for its iLet automated insulin delivery system, which contributed to investor concerns about near-term adoption trends and revenue growth [5]. - Following the announcement, Beta Bionics' stock price dropped approximately $11.85, or 37.04%, closing at $20.14 on the same day [5]. Group 2: Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics for investors who suffered significant losses due to the stock's decline [2][4]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses in Beta Bionics to Contact Him Directly to Discuss Their OptionsIf you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - January 14, 2026) - Faruq ...